



This is a repository copy of *How do paediatricians use and monitor antithyroid drugs in the UK? A clinician survey.*

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/148158/>

Version: Accepted Version

---

**Article:**

Lawrence, N., Cheetham, T. and Elder, C. [orcid.org/0000-0003-2390-5593](https://orcid.org/0000-0003-2390-5593) (2019) How do paediatricians use and monitor antithyroid drugs in the UK? A clinician survey. *Clinical Endocrinology*, 91 (3). pp. 417-423. ISSN 0300-0664

<https://doi.org/10.1111/cen.14046>

---

This is the peer reviewed version of the following article: Lawrence, N, Cheetham, T, Elder, C. How do paediatricians use and monitor antithyroid drugs in the UK? A clinician survey. *Clin Endocrinol (Oxf)*. 2019; 00: 1– 7, which has been published in final form at <https://doi.org/10.1111/cen.14046>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>



**How do paediatricians use and monitor anti-thyroid drugs in the UK? A clinician survey**

Journal:	<i>Clinical Endocrinology</i>
Manuscript ID	CEN-2019-000277.R1
Manuscript Type:	1 Original Article - UK, Europe
Date Submitted by the Author:	n/a
Complete List of Authors:	Lawrence, Neil; Sheffield Children's NHS Foundation Trust, Paediatrics; Cheetham, Tim; Royal Victoria Infirmary, Queen Victoria Road, Paediatrics Elder, Charlotte; University of Sheffield, Academic Unit of Child Health; Sheffield Children's Hospital, Endocrinology
Key Words:	Thionamide < Investigations & Rx: < Thyroid, Carbimazole < Investigations & Rx: < Thyroid, Immunosuppression < Investigations & Rx: < Thyroid, Graves disease < Conditions: < Thyroid, Hyperthyroidism < Conditions: < Thyroid

**How do paediatricians use and monitor anti-thyroid drugs in the UK? A clinician survey**

Authors: Neil Lawrence<sup>1</sup>, Tim Cheetham<sup>2</sup>, Charlotte Elder<sup>1,3</sup>

Corresponding Author: Neil Lawrence. E-mail: neilxlawrence@gmail.com

1. Sheffield Children's Hospital NHS Foundation Trust, Western Bank, Sheffield, S10 2TH, UK

2. Newcastle University c/o Department of Paediatric Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP

3. The University of Sheffield, Western Bank, Sheffield, S10 2TN, UK

Acknowledgements: The authors would like to thank the committee of the BSPED for disseminating this survey and the respondents for providing an account of current practice.

## Summary

Objective: We aimed to document current practice in the medical management of paediatric hyperthyroidism in the UK and compare to international recommendations.

Design: A 27 question online survey distributed via an electronic newsletter in August 2018.

Participants: Responses from 48 members (11%) of the British Society for Paediatric Endocrinology and Diabetes.

Measurements: Information about anti-thyroid drug (ATD) preference, treatment duration, monitoring of full blood count (FBC), management of neutropaenia, agranulocytosis screening and patient education.

Results: Carbimazole is favoured by 98% of respondents and a 'dose titration' regimen preferred over 'block and replace' (65% versus 29%). TRAbs (Thyroid Stimulating Hormone Receptor Antibodies) are used for diagnostic purposes by 85% and by 33% to look for evidence of disease remission. The majority (81%) treat for a minimum of 2 years before considering a trial off ATD. All respondents reported that they 'always/usually' warn their patients about the risk of agranulocytosis before starting ATD, but written information is 'rarely/never' provided by 63%. Sore throat (98%) and fever (92%) are the most commonly cited symptoms used to alert a patient to possible agranulocytosis. FBC is measured prior to treatment by 65% and measured periodically during treatment by 70%.

Conclusions: The management of paediatric hyperthyroidism with ATDs in the UK is not consistent with all international recommendations because a block and replace ATD regimen remains widely used. TRAbs are utilised at presentation, but under-used for detecting disease remission. National consensus guidelines and written patient information may refine the management of paediatric patients on ATDs.

**Key Words**

Hyperthyroidism, Immunosuppression, Graves disease, Carbimazole, Thionamide

**Conflict of Interest**

The authors report no conflict of interests that could be perceived as prejudicing the impartiality of the research reported.

**Data Availability Statement**

The data that support the findings of this study are openly available in "figshare" at <https://doi.org/10.6084/m9.figshare.7962839.v1> and <https://doi.org/10.6084/m9.figshare.7962860.v1>.

## 1 Introduction

The incidence of hyperthyroidism in children in the UK and Ireland is 0.9 per 100,000 and is due to underlying Graves' disease in 96% of cases.<sup>1</sup> Medical treatment consists of thionamide anti-thyroid drug (ATD) using Carbimazole (CBZ), its active metabolite Methimazole, or Propylthiouracil (PTU). Only CBZ and PTU are available in the UK. The United States Food and Drug Administration released a warning in 2010 regarding the increased risk of hepatotoxicity associated with PTU in children and, as a result, CBZ is recommended as first-line treatment, with the exception of the first trimester of pregnancy.<sup>2-6</sup> ETA (European Thyroid Association) and ATA (American Thyroid Association) guidelines advise on treatment for adults and children. Both advocate the use of CBZ over PTU in children. The ATA recommend a treatment duration of 12-24 months, and the ETA a treatment duration of 36 months prior to stopping ATD therapy in children to check for remission.<sup>2,3</sup> JTA (Japanese Thyroid Association) guidelines are paediatric specific and recommend treatment with Methimazole for a duration of 18-24 months.<sup>4</sup>

ATD therapy typically involves either titrating the dose of ATD until the patient becomes euthyroid (dose titration, DT) or maintaining a high dose of ATD to suppress endogenous thyroid production and then replacing thyroid hormone with Levothyroxine (block and replace, BR). BR may require fewer hospital visits and blood tests whilst DT is associated with fewer ATD side-effects because of the lower ATD dose.<sup>1,3,7</sup> ETA guidelines do not advocate one treatment regimen over the other but the ATA recommend DT. JTA guidelines recommend avoiding BR, citing the 2010 Cochrane Collaboration review that identified an increased risk of adverse reactions with this treatment strategy when compared to DT.<sup>4,7</sup> However it has been highlighted that some of the studies included in the Cochrane review, and in the BR section of the analyses, used an ATD dose that was much higher than routinely used in clinical practice.<sup>8</sup> The Cochrane review also focused on the use of ATD in the context of adults and not the management of children and adolescents.

A rare but potentially fatal side effect of ATD therapy is agranulocytosis, defined as an absolute neutrophil count (ANC) of  $< 0.5 \times 10^9/L$ .<sup>9</sup> It is important that patients are aware of the need to have their full blood count (FBC) checked when they experience symptoms suggestive of agranulocytosis. Symptoms are non-specific, most commonly fever and sore throat in adults presenting with agranulocytosis secondary to ATDs.<sup>10</sup> Although it is recommended that patients are provided with written information about the risk of agranulocytosis, international guidelines do not specify symptoms which should trigger consideration of agranulocytosis or measurement of an FBC.<sup>2,3</sup> Recommendations in the UK suggest that three measures should be taken to manage the risk of

1 agranulocytosis: Patients should be asked to report symptoms of infection; a white blood cell count should be  
2 performed when there is clinical evidence of infection; and CBZ should be stopped promptly if there is clinical or  
3 laboratory evidence of neutropaenia.<sup>11</sup>  
4

5  
6  
7 We set out to establish the current approach to ATD use in children in the UK. We also sought to understand how  
8 the risk of agranulocytosis is managed, exploring how clinicians might respond to blood tests demonstrating a low  
9 white cell count. We also explored clinician's use of TRAb (Thyroid Stimulating Hormone Receptor Antibody)  
10 measurement and the typical duration of ATD treatment in children with hyperthyroidism.  
11  
12  
13  
14  
15

## 20 **2 Materials and Methods**

21  
22  
23 We reviewed the NICE 'Important Safety Information' for Carbimazole,<sup>11</sup> and the advice pertaining to safe  
24 prescribing of ATDs within international guidelines.<sup>2,4</sup> We then developed 27 questions that examined both  
25 adherence to published advice and the use and interpretation of related diagnostic tests, and compiled these into an  
26 online survey using 'Google Forms' (Google Drive Office Suite, Alphabet inc., Mountain View, CA, USA). We  
27 advertised the survey in the BSPED (British Society for Paediatric Endocrinology and Diabetes) newsletter e-mailed to  
28 all members in July and August of 2018, with a subsequent follow up email designed to boost the response rate.  
29  
30  
31  
32  
33  
34  
35

36 Respondents could choose to remain anonymous if preferred. The questions were multiple choice but 13 of the  
37 questions also included an option for free text. The full list of questions in the survey can be found at  
38 [goo.gl/forms/7gbi8MnV6uZ7Umyg2](https://goo.gl/forms/7gbi8MnV6uZ7Umyg2).  
39  
40  
41  
42

43 The first seven questions sought demographic data about the respondent, the service that they work in as well as  
44 establishing whether a hyperthyroidism guideline was in use. Three questions elicited their ATD of choice, whether  
45 they had a preference for DT or BR and whether they perform an FBC prior to ATD initiation. Respondents were then  
46 posed six questions exploring whether patients are warned about agranulocytosis, whether this includes written  
47 patient information, whether the warnings are repeated at follow up and whether there is a systemic warning  
48 system in place to remind clinicians to discuss the risk of agranulocytosis. We further explored the management of  
49 agranulocytosis with two questions pertaining to how patients are taught to recognise and react to agranulocytosis,  
50 and a question regarding the clinicians' actions should they be confronted with a range of low neutrophil counts. The  
51 following three questions explored the use of TRAbs and other factors that might influence the length of ATD  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 treatment, with four further questions about the experience of the respondent within paediatric endocrinology and  
2 how many cases of agranulocytosis or hepatic impairment they had encountered secondary to ATD use. We used  
3 conditional branching within the survey to divert respondents away from questions that were not relevant to them.  
4  
5 The survey remained open to responses for 6 weeks.  
6  
7  
8  
9

10 We used descriptive statistics to quantify responses to each question, calculating the percentage of responses to  
11 each question using the number of respondents to that question as the denominator. We collated and analysed data  
12 within Microsoft Excel (MSO 16, Microsoft Corporation, Redmond, WA, USA).  
13  
14  
15  
16

17 As the study was a survey on healthcare provision and did not collect individual patient information, research ethics  
18 approval was not required.  
19  
20  
21  
22  
23  
24

### 25 **3 Results**

#### 26 **3.1 Demographics**

27  
28 The BSPED committee sent the newsletter to 437 members, of whom 266 are medical consultants. We received a  
29 total of 48 responses (11%), of which 32 were from clinicians in a tertiary centre and 16 from a secondary centre.  
30 Respondents comprised 30 consultant paediatric endocrinologists, 16 consultant paediatricians with a special  
31 interest in endocrinology, and two paediatric doctors in training. Contact details left voluntarily by half of  
32 respondents (24/48) revealed that half of the major conurbations in England and Wales with tertiary endocrine  
33 units were represented by these individuals alone..  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 Respondents collectively reported 519 years of experience in paediatric endocrinology, with 63% (30/48) of  
46 respondents having over 10 years of experience in the field and only three respondents reporting less than two years  
47 of experience in the field. The majority (54%, 26/48) of respondents had never encountered a patient with  
48 agranulocytosis secondary to ATD use, whilst 44% (21/48) had seen one or two cases, and one individual three or  
49 four cases.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### 3.2 Management of Hyperthyroidism

Guidelines for the treatment of hyperthyroidism are used by 21% (10/48) of respondents. Five use a local trust guideline, one a local network guideline, and four a national or international guideline. CBZ is the first line ATD used by 98% (47/48) of respondents, with 65% (31/48) reporting a preference for DT, 29% (14/48) for BR and 6% (3/48) reporting no preference (Figure 1).

TRAb's are used to assist diagnosis by 85% (41/48) of respondents, although fewer employ them to predict prognosis (46%, 22/48), check for remission (33%, 16/48), or monitor treatment (8%, 4/48) (Figure 2). Length of time on treatment is typically used to gauge when to trial patients off treatment (94%, 45/48), although where the young person is in relation to important educational milestones, such as examinations, is also frequently considered (79%, 38/48). A majority of 81% (39/48) of respondents consider two years as the minimum duration of treatment prior to a trial off ATDs, while six respondents reported a year or less and one reported a minimum of five years.

### 3.3 Agranulocytosis

All respondents reported that they 'always' or 'usually' warn their patients about the risk of agranulocytosis before starting ATD treatment, with 70% (32/46) reporting they then discuss the risk of agranulocytosis 'usually' or 'at every appointment' during follow up. However, written information about agranulocytosis is 'rarely' or 'never' provided by 63% (30/48). When educating patients about how to recognise a possible case of agranulocytosis, the symptoms that clinicians mention most frequently to patients are sore throat (98%, 47/48), fever (92%, 44/48) and oral ulcers (44%, 21/48).

Prior to starting a patient on an ATD, 88% (42/48) measure an FBC. On follow up 28% (13/46) check an FBC every time they measure thyroid function and 65% (30/46) 'on an *ad hoc* basis' (Figure 3). Responses to a question seeking the definition of agranulocytosis were equally split between correctly identifying this as an absolute neutrophil count (ANC) of  $< 0.5 \times 10^9/L$  (40%, 19/48) and the same proportion defining it as an ANC  $< 1.0$  (40%, 19/48). When asked how to manage a low neutrophil count, 35% (17/48) would admit a patient with an ANC  $< 0.5 \times 10^9/L$  to hospital, whilst 54% (26/48) would advise stopping the ATD and rechecking the FBC the next day as an outpatient. The management of a low neutrophil count was dependent upon the absolute neutrophil number with 8% (4/48)

1 stopping the ATD at a neutrophil count  $< 2.0 \times 10^9/L$  and 90% (43/48) stopping the ATD at a neutrophil count  $< 0.5$   
2  $\times 10^9/L$  (Figure 4).<sup>12</sup>  
3  
4  
5  
6  
7

## 8 Discussion

10 This is the first nationwide clinician survey studying the current approaches to the management of hyperthyroidism  
11 in children in the UK. Previous surveys of adult clinicians have shown international variation in the management of  
12 hyperthyroidism,<sup>13,14</sup> but preferences around the use of ATDs in children are unknown. The fact that such a  
13 substantial proportion of the large conurbations in the UK were represented by the respondents who highlighted  
14 their place of work leads us to believe that this survey is a meaningful representation of current UK endocrine  
15 practice.  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 We identified a preference among clinicians to use the DT approach to ATD administration rather than BR, which is  
26 in keeping with a 2013 European survey into adult practice.<sup>13</sup> Level 1 evidence of superiority of one ATD regimen  
27 over the other is lacking in paediatric practice. A Cochrane review in 2010, involving primarily adult patients, found  
28 relapse rates to be similar with both regimens, but a higher rate of side effects when using BR.<sup>7</sup> A BR regimen may  
29 have the advantage of necessitating fewer trips to the outpatients department, but the disadvantage of an extra  
30 medication burden for the patient,<sup>16</sup> and the increased rate of side effects has led the ATA to suggest avoiding this  
31 approach.  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Most respondents (85%) use TRAbs to aid diagnosis of Graves' disease, which have been shown to shorten time to  
42 diagnosis and reduce management costs.<sup>17</sup> TRAbs are also recommended by the ATA and ETA to assist in predicting  
43 the likelihood of remission and to inform on the decision to wean ATD dose. Adult remission rates of over 80% are  
44 reported in cohorts with low or undetectable TRAbs compared to 20-30% in cohorts that have persistently elevated  
45 TRAbs.<sup>18,19</sup> Whilst 33% of respondents are monitoring TRAbs for this indication, there is the potential to increase  
46 their use to improve remission rates in the paediatric cohort. UK clinicians continue patients on ATDs for two years  
47 prior to a trial off treatment, longer than the 12-18 months suggested in the ATA guidelines, but less than the 3 years  
48 suggested by the ETA and 5-10 years by the JTA.<sup>2-4</sup>  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Whilst clinicians in this survey report consistently informing patients about the risk of agranulocytosis, the  
proportion who regularly provide written information, as advised in both ATA and ETA guidelines, is low (37%).

1 Although advised, neither the ATA nor ETA provide a standardised patient information leaflet. In the UK, the  
2 Medicines for Children partnership programme have produced a patient information leaflet entitled 'Carbimazole for  
3 hyperthyroidism'.<sup>20</sup> This is over 1500 words long and, whilst informing patients about the risk of agranulocytosis,  
4 does not instruct them beyond 'contact your doctor straight away'. The British National Formulary, under 'important  
5 information about Carbimazole', states that CBZ should be stopped pending an FBC should the patient experience  
6 symptoms and signs of infection.<sup>11</sup> There is evidence that supplying patient information leaflets about medication  
7 increases patient knowledge about side effects as well as improving patient satisfaction.<sup>21</sup> We postulate that a short,  
8 simple patient information leaflet would increase the proportion of families and patients receiving and  
9 comprehending written information about CBZ. The leaflet would aim to increase awareness of agranulocytosis, with  
10 specific guidance to stop ATD therapy pending an FBC if symptoms of fever, sore throat or oral ulcers occur. These  
11 are the most frequent symptoms associated with agranulocytosis secondary to ATD use.<sup>10</sup>

12 Agranulocytosis is not the only side effect of CBZ but it is unique in combining frequently experienced and commonly  
13 innocuous symptoms such as sore throat and fever with a potentially fatal outcome. Pancreatitis has recently been  
14 highlighted as a recognised side effect,<sup>22</sup> alongside the risk of liver dysfunction or vasculitis.<sup>2</sup> We believe that these  
15 conditions have presenting features more likely be recognised as potentially pathological by patients or carers.

16 ATA and ETA guidelines recommend a more conservative approach to laboratory proven agranulocytosis than was  
17 demonstrated by the clinicians responding to our survey. Whilst 90% of respondents would stop the ATD with an  
18 ANC < 0.5x10<sup>9</sup>/L, only 35% would admit to hospital. It is important to note that rates of death in children with  
19 agranulocytosis secondary to ATD have been shown to be as high as 4%,<sup>23</sup> and thus treatment with intravenous  
20 broad-spectrum antibiotics is recommended.<sup>24</sup> However, we are wary of drawing too significant a conclusion from  
21 survey data into hypothetical patient management decisions, particularly as the option to discuss blood results with  
22 an expert in the field (i.e. a haematologist) was not available in our multiple choice questions.

23 In this survey, 70% of respondents reported they check an FBC with some degree of regularity. Routine monitoring of  
24 FBC for patients taking ATDs was considered unnecessary by the WHO (World Health Organisation) in 1999 due to  
25 the often abrupt onset of agranulocytosis.<sup>25</sup> This advice is reflected in ETA and ATA guidelines,<sup>2,3</sup> although JTA  
26 guidelines advise undertaking regular monitoring of white cell count during the first 3 months of treatment.<sup>4</sup> This  
27 timescale is consistent with data from UK reports of adverse drug reactions in adults prescribed CBZ showing a  
28 median onset of agranulocytosis of 31 days (range 14-105)<sup>26</sup>, although cases have been described that have occurred

1 up to 11 years after the start of treatment.<sup>27</sup> Checking a FBC prior to the start of treatment, carried out by 88% of our  
2 respondents as recommended in ATA guidelines, can help to determine whether a low white cell count is due to ATD  
3 therapy or the disease itself. There is an association between untreated Graves' disease and the development of  
4 neutropenia, a finding more common in non-Caucasian patients and those with higher serum thyroid hormone  
5 levels.<sup>28</sup>

6  
7  
8  
9  
10  
11  
12 We recognise that our survey has limitations. Online clinician surveys are reported to garner a typical response rate  
13 of less than 20%,<sup>15</sup> and whilst our response rate of 11% is low in the context of the entire membership of the BSPED,  
14 this should be considered within the context of a membership that includes allied health professionals and a large  
15 proportion of clinicians who manage children with diabetes rather than endocrine conditions. A response rate of  
16 40% has previously been demonstrated in another UK survey of Thyroid disease<sup>29</sup>, but only within targeted email  
17 requests to consultants known to have an interest in the disease. Some BSPED members will be from small units with  
18 no recent experience of managing hyperthyroidism, or practice mainly or exclusively with patients with diabetes. In  
19 the case of some units, we know that one BSPED member responded on behalf of the team on the basis that they  
20 were representing their departmental strategy. Selection bias may have influenced the results with those with an  
21 interest in thyroid disease being more likely to respond and thus disproportionately reporting preferences made by  
22 specialists within the field. Recall bias may have influenced such a high proportion of respondents (100%) reporting  
23 that they always or usually discuss the risk of agranulocytosis with patients/carers. A local audit of patient notes in  
24 Sheffield revealed only 50% (7/14) of consultations where an ATD was initiated included documentation about the  
25 risk of agranulocytosis, and no documentation that patients were informed to stop the drug should it be suspected.<sup>30</sup>  
26 Knowledge of adult patients about the risk of agranulocytosis secondary to ATDs has been shown to be poor despite  
27 the information being verbally delivered by clinicians,<sup>31</sup> reinforcing the importance of providing this information in  
28 the written form.

29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51 In conclusion, this survey has shown that choice of ATD and duration of treatment by clinicians in the UK is  
52 consistent with current international recommendations, although a substantial proportion of children are still  
53 managed using a BR regimen despite the ATA guideline advising against this practice. The outcome of a UK  
54 randomised trial comparing biochemical control in young patients managed with either BR and DT is expected  
55 imminently and may help to guide and refine clinical practice further.<sup>32</sup> The measurement of TRAbs to aid diagnosis  
56 is a common practice but under-utilised in relation to detecting likelihood of disease remission and hence the timing

1 of ATD cessation. It appears that the majority of clinicians are managing hyperthyroidism without a guideline,  
2 perhaps contributing to the variation in practice demonstrated, and unable to backup verbal advice about  
3 agranulocytosis with written information. Patient education is at the heart of patient safety and it seems timely that  
4 a national guideline and patient information leaflet to support the management of paediatric patients on ATDs is  
5 considered.<sup>24</sup>  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

## References

1. Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. *Clin Endocrinol (Oxf)*. 2010;72(3):358-363.
2. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid*. 2016;26(10):1343-1421.
3. Kahaly G, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. *European Thyroid Journal*. 2018;7(4):167-186.
4. Minamitani K, Sato H, Ohye H, Harada S, Arisaka O. Guidelines for the treatment of childhood-onset Graves' disease in Japan, 2016. *Clin Pediatr Endocrinol*. 2017;26(2):29-62.
5. Maia AL, Scheffel RS, Meyer EL, et al. The Brazilian consensus for the diagnosis and treatment of hyperthyroidism: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. *Arq Bras Endocrinol Metabol*. 2013;57(3):205-232.
6. Rivkees SA. 63 Years and 715 Days to the "Boxed Warning": Unmasking of the Propylthiouracil Problem. *Int J Pediatr Endocrinol*. 2010;2010.
7. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. *Cochrane Database Syst Rev* 2010:CD003420.
8. Razvi S, Vaidya B, Perros P, Pearce SH. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. *Eur J Endocrinol*. 2006;154(6):783-786.
9. Benichou C, Solal Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. *Nouv Rev Fr Hematol*. 1991;33(3):257-262.
10. Sheng WH, Hung CC, Chen YC, et al. Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections. *Qjm*. 1999;92(8):455-461.
11. Paediatric Formulary Committee. *BNF for Children*. Vol 2018-2019: RCPCH Publications Limited; 2018.
12. [dataset] Lawrence N, Cheetham T, Elder C. Paediatric Hyperthyroidism - UK Survey of Clinicians. Figshare. DOI <https://doi.org/10.6084/m9.figshare.7962839.v1>.
13. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves' disease. *Clin Endocrinol (Oxf)*. 2016;84(1):115-120.


- 1 14. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves'  
2 disease. *J Clin Endocrinol Metab.* 2012;97(12):4549-4558.  
3
- 4 15. Dykema J, Jones NR, Piche T, Stevenson J. Surveying clinicians by web: current issues in design and  
5 administration. *Eval Health Prof.* 2013;36(3):352-381.  
6
- 7 16. Bartalena L. Diagnosis and management of Graves disease: a global overview. *Nat Rev Endocrinol.*  
8 2013;9(12):724-734.  
9
- 10 17. McKee A, Peyerl F. TSI Assay Utilization: Impact on Costs of Graves' Hyperthyroidism Diagnosis. *American*  
11 *Journal of Managed Care.* 2012;18(1):E1-E8.  
12
- 13 18. Carella C, Mazziotti G, Sorvillo F, et al. Serum thyrotropin receptor antibodies concentrations in patients with  
14 Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the  
15 activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.  
16 *Thyroid.* 2006;16(3):295-302.  
17
- 18 19. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Topping O. TSH-receptor autoimmunity in  
19 Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective  
20 randomized study. *Eur J Endocrinol.* 2008;158(1):69-75.  
21
- 22 20. Medicines for Children. Carbimazole for hyperthyroidism.  
23 <https://www.medicinesforchildren.org.uk/carbimazole-hyperthyroidism>. Published 2016. Accessed April 2,  
24 2019.  
25
- 26 21. Gibbs S, Waters WE, George CF. Prescription information leaflets: a national survey. *J R Soc Med.*  
27 1990;83(5):292-297.  
28
- 29 22. Agarwal A. Medicinal products containing carbimazole or thiamazole (synonym: methimazole): (1)  
30 strengthened advice on contraception and (2) risk of acute pancreatitis [press release]. Direct mailing:  
31 Amdipharm Ltd.2019.  
32
- 33 23. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced  
34 agranulocytosis over 30 years in Japan. *J Clin Endocrinol Metab.* 2013;98(12):4776-4783.  
35
- 36 24. Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid Drug-Induced Agranulocytosis: State of the Art on  
37 Diagnosis and Management. In: *Drugs R D.* Vol 17.2017:91-96.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
25. The Committee on Safety of Medicines [World Health Organisation]. WHO Pharmaceuticals Newsletter 1999, No. 03&04: Drug surveillance: Anti-thyroid drugs: agranulocytosis: UK. <http://apps.who.int/medicinedocs/en/d/Js2271e/2.3.html>. Published 1999. Accessed April 2, 2019.
26. Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. *Clin Endocrinol (Oxf)*. 2004;61(5):589-594.
27. Mutharasan P, Oatis W, Kwaan H, Molitch M. Delayed antithyroid drug-induced agranulocytosis. *Endocr Pract*. 2012;18(4):e69-72.
28. Aggarwal N, Tee SA, Saqib W, Fretwell T, Summerfield GP, Razvi S. Treatment of hyperthyroidism with antithyroid drugs corrects mild neutropenia in Graves' disease. *Clin Endocrinol (Oxf)*. 2016;85(6):949-953.
29. Vaidya B, Williams GR, Abraham P, Pearce SHS. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. *Clinical Endocrinology*. 2008;68(5):814-820.
30. [dataset] Lawrence N, Elder C. Local Use of Anti-Thyroid Drugs in Sheffield. Figshare. <https://doi.org/10.6084/m9.figshare.7962860.v1>.
31. Robinson J, Richardson M, Hickey J, et al. Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis. *Eur Thyroid J*. 2014;3(4):245-251.
32. Cheetham T. Study of two anti-thyroid drug treatment regimens in young people with thyrotoxicosis. Springer Nature. ISRCTN Registry Web site. <http://www.isrctn.com/ISRCTN82088322>. Published 2011. Updated 23/01/2018. Accessed April 2, 2019.




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1: Preference for Anti-Thyroid Drug Treatment Regimen**




Peer Review

1  
2  
3 **Figure 2: The Measurement of TRAbs in relation to ATD treatment**  
4  
5




26 TRAbs = Thyroid Receptor Antibody Tests. ATD = Anti-Thyroid Drug  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 3: The measurement of FBC in relation to ATD treatment



FBC = Full Blood Count. ATD = Anti-Thyroid Drug. TFT = Thyroid Function Test

Figure 4: Actions clinicians recommend after a low ANC



ANC = Absolute Neutrophil Count. ATD = Anti-Thyroid Drug. FBC = Full Blood Count

Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60